Adobe Discusses Its Life Science Strategy


By Salvatore Salamone Bio-IT World

With most pharmaceutical companies counted as customers, and electronic submissions to the FDA requiring documents to be in PDF format, Adobe is no stranger to the life sciences.

But the company has been reinforcing its ties to the industry with a concerted life science effort that has a dedicated staff of industry experts.

“The vertical focus on the life sciences is new, but [Adobe’s] work in the area is not new,” says Melonie Warfel, director of Adobe Life Sciences.

The life science effort at Adobe is an umbrella program that covers pharmaceutical, biotech, and medical device companies. Part of the effort is ensuring that documents meet FDA submission and other regulatory requirements. Within the pharmaceutical industry, the program targets a wide range of application areas, including R&D, clinical development, regulatory affairs, manufacturing, and marketing and sales.

Warfel notes that many of the business trends and business priorities that the Life Sciences group deals with are not new. “Our customers say they need to maintain their competitive advantage, comply with regulatory requirements, and protect their intellectual property,” says Warfel.

What is new is the amount of information that is being collected in life science organizations today. Adobe sees its strength in helping companies gather, present, and safely share this information.

Part of the life science effort is tied to a transformation within Adobe. The company has quietly morphed from a desktop software company to a server software company. The fruits of this change can be seen in its Adobe Intelligent Platform architecture, which is made up of the universal client, intelligent documents, and Adobe document services.

Most people are familiar with the universal client aspect of Adobe’s architecture. This is basically the client software – the Acrobat Reader and Web browser plug-in – that allows workers, partners, and others to access and work with documents. With the client software, people can share documents within and outside a company and documents can be accessed using virtually any platform ranging from a PC to a PDA (personal digital assistant) to a cell phone.

And while the universal client is essential in any company, it is the other parts of the Intelligent Platform architecture that have great potential and application in the life sciences.

Specifically, Adobe’s intelligent documents combine Adobe PDF and XML technology. This enables a digital document to keep the look and feel of a paper document while allowing life science companies to embed business functions within the document. For instance, intelligent documents can include error checking while data is being entered, data validation, and routing of information such as parts of a document or an entire document.

Architecturally above the intelligent documents is what is known as the Adobe Document Services. Among the features supported within the Document Services offerings are things like document generation, document control and security, collaboration, and process management.

For example, when it comes to document control and security Adobe offers the Adobe LiveCycle Policy Server for managing and monitoring electronic forms, and Adobe LiveCycle Document Security, which offers encryption and digital signature features for safeguarding the content of an electronic document. The LiveCycle line of enterprise products also includes a handful of document-generation and process-management offerings.

Part of the Life Sciences group’s strategy is to work with partners such as Accenture, EMC/Documentum, IBM, Open Text, Oracle Clinical, and others. Members of the Adobe Life Sciences group also take active roles in many of the industry standards development efforts.

Are you using more electronic forms to collect data? What technologies and formats are important to you? PDF? XML? eCTD? Who are you turning to for help in these areas? Drop me a note at Salvatore_Salamone@bio-itworld.com and share your thoughts on this topic.

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.